UroGen Q3 Jelmyto rev $11.4M; ends Allergan pact; shifts UGN-102 trial to single-arm Phase 3

UroGen Pharma Ltd.

Q3 2021 net product revenue $11.4M; net loss $30.2M ($1.35/share) vs $28.8M loss ($1.31) in Q3 2020.
Full-year 2021 revenue guidance $47-51M; operating expense guidance reduced to $137-142M from $155-165M.
Ceased enrollment in ATLAS Phase 3 for UGN-102; new single-arm Phase 3 trial planned for early 2022; NDA submission expected 2024.
Mutually terminated license agreement with Allergan effective November 11, 2021.
Cash and equivalents $110.3M as of Sep 30; Jelmyto site activations up 73% since August 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.